Baseline clinical characteristics in 13 patients
Characteristic . | No. of patients . | Percentage . |
|---|---|---|
| Sex | ||
| Female | 4 | 31 |
| Male | 9 | 69 |
| Stage | ||
| I | 6 | 46 |
| II | 0 | 0 |
| III | 3 | 23 |
| IV | 4 | 31 |
| WBCs, × 109/L | ||
| 20 or fewer | 3 | 23 |
| 20-50 | 4 | 31 |
| 50 or more | 6 | 46 |
| Indication for treatment | ||
| Symptomatic/unacceptable adenopathy | 3 | 23 |
| Rapid lymphocyte doubling time | 2 | 15 |
| Symptomatic splenomegaly | 0 | 0 |
| B symptoms: fatigue, weight loss, and night sweats | 4 | 31 |
| Progressive autoimmune thrombocytopenia/anemia | 1 | 8 |
| Advanced-stage disease | 6 | 46 |
| Interphase cytogenetics* | ||
| Normal | 2 | 15 |
| Trisomy 12 | 3 | 23 |
| p53 deletion | 1 | 8 |
| Deletion 13q | 1 | 8 |
Characteristic . | No. of patients . | Percentage . |
|---|---|---|
| Sex | ||
| Female | 4 | 31 |
| Male | 9 | 69 |
| Stage | ||
| I | 6 | 46 |
| II | 0 | 0 |
| III | 3 | 23 |
| IV | 4 | 31 |
| WBCs, × 109/L | ||
| 20 or fewer | 3 | 23 |
| 20-50 | 4 | 31 |
| 50 or more | 6 | 46 |
| Indication for treatment | ||
| Symptomatic/unacceptable adenopathy | 3 | 23 |
| Rapid lymphocyte doubling time | 2 | 15 |
| Symptomatic splenomegaly | 0 | 0 |
| B symptoms: fatigue, weight loss, and night sweats | 4 | 31 |
| Progressive autoimmune thrombocytopenia/anemia | 1 | 8 |
| Advanced-stage disease | 6 | 46 |
| Interphase cytogenetics* | ||
| Normal | 2 | 15 |
| Trisomy 12 | 3 | 23 |
| p53 deletion | 1 | 8 |
| Deletion 13q | 1 | 8 |
Median age of patients was 65 years (range, 38-74 years).
Available on 7 patients only.